ROCKVILLE, MD--(Marketwire - August 11, 2008) - RemeGenix, Inc. today announced receipt of a $100K investment from the Alzheimer’s Drug Discovery Foundation (ADDF). The focus of the funding is to advance the commercial development of peptides derived from BRI2 that can be used to reduce the toxic impact of A-beta (in several complementary ways), ultimately treating the cause, versus the symptoms, of Alzheimer’s disease. The work will be done in collaboration with scientists at the Albert Einstein College of Medicine, Yeshiva University.
